CytRx wishes on STAR-1 in hopes FDA will accelerate tamibarotene
This article was originally published in Pharmaceutical Approvals Monthly
CytRx is "aggressively working to achieve our goal" of completing the pivotal Phase II STAR-1 trial of oral tamibarotene for third-line treatment of acute promyelocytic leukemia by year-end, the company says June 29. The effort "may include acceleration of the trial through a negotiation with the FDA regarding the total number of patients ultimately enrolled." CytRx has been taking advantage of FDA programs to speed development of drugs for high-need settings, like APL; according to the company, approximately 1,500 patients are diagnosed with the rare cancer annually in the U.S. Tamibarotene, which would be the first approval for APL, has orphan status and fast-track status for relapsed or refractory APL, and the open-label, non-randomized STAR-1 trial is being conducted under a Special Protocol Assessment. The pivotal trial has enrolled 11 patients to date, and five of the patients have achieved a morphologic leukemia-free state, when no leukemia cells can be found in bone marrow, the company reports. MLFS is one of several criteria comprising the primary endpoint of durable complete response
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.